Various Radiopharmaceuticals
Contract Opportunity Analysis
The Department of Defense, specifically the Department of the Army, intends to award a sole source contract to RLS Inc. for the procurement of various FDA-approved radiopharmaceuticals, including products such as I-131 and others listed in Table 1 (Illucix, Netspot, Locametz, Detectnet). This procurement is critical for medical readiness and will support the operational needs of the Army, ensuring access to essential radiopharmaceuticals for diagnostic and therapeutic purposes. The performance period for this Firm-Fixed-Price contract is set from October 1, 2025, to September 30, 2026, with an anticipated award date of September 15, 2025. For further inquiries, interested parties may contact Derrick J Johnson at derrick.j.johnson2.civ@health.mil or by phone at 210-221-4811.